PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced ...

In LAVA-1207’s absence, Lava will now be bumping up LAVA-1266, which is due to enter the clinic before the end of the year.

IN8bio (INAB) announced updated data from the ongoing Phase 1 trial of INB-100, an allogeneic, haploidentical gamma-delta T cell therapy in ...

GammaDelta’s drug platform is based on the unique properties of gamma delta (γδ) T cells, a class of lymphocytes that play a role to many types of immune responses and immunopathology.

The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant ...

East Ocyon Bio aims to reshape Indias role in the global biotech landscape, creating an ecosystem where pioneering therapies ...

TC BioPharm (TCBP) announced a partnership with CareDx (CDNA) who will perform pharmacokinetic analysis using its AlloCellsolution in the ...

Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA ...

As of September 30, 2024, LAVA had cash, cash equivalents and investments totaling $78.9 million, compared to cash, cash equivalents and investments of $95.6 million as of December 31, 2023. The ...

Biotech startup East Ocyon Bio, fashion platforms Culture Circle and Mhyth, fintech startup Navanc and personal health ...

TC Biopharm (NASDAQ:TCBP – Get Free Report) had its price target reduced by HC Wainwright from $7.00 to $3.00 in a report released on Friday, Marketbeat reports. The brokerage presently has a “buy” ...